Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
For-Robin
AddedFeb 16, 2024
UpdatedJun 18, 2026
For-Robin

For-Robin

For-Robin Therapeutics, a US-based company, develops antibody immunotherapy for all breast cancer types, including triple negatives.

HQ
New York City, NY, US
Founded
2012
Overview
Compare
Fundraising
Employees
Website

For-Robin Therapeutics, founded in Williamsville, United States, is dedicated to developing antibody immunotherapy for breast cancer treatment. Named in honor of the founder’s sister, Robin Quataert, who passed away from estrogen and progesterone receptor-negative breast cancer, the company’s mission is to provide effective treatments for all breast cancer subtypes, particularly triple-negative breast cancer. Their proprietary technology includes the monoclonal antibody JAA-F11 and its humanized variants, which target a broad spectrum of breast cancer cells.

Notable affiliations include partnerships with the National Cancer Institute's NExT program, supporting IND-enabling antibody production and safety studies. Key achievements involve advancing their proprietary antibodies towards clinical trials scheduled for 2023-24. For-Robin's impact lies in its potential to offer targeted therapy options for breast cancer patients, addressing a critical unmet need in oncology.

For-Robin - Similar Companies

Robin Care logo

Robin Care

SunnyBay BioTech logo

SunnyBay BioTech

Grid Therapeutics logo

Grid Therapeutics

Nantkwest logo

Nantkwest

Neoantigenics logo

Neoantigenics

Fore Biotherapeutics logo

Fore Biotherapeutics

fore.bio

Robin logo

Robin

Palm Therapeutics logo

Palm Therapeutics

Ribon Therapeutics logo

Ribon Therapeutics

ribontx.com

OncoResponse logo

OncoResponse

Quantum Immunologics logo

Quantum Immunologics

EtiraRx logo

EtiraRx

etirarx.com

Fortis Therapeutics logo

Fortis Therapeutics

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Resonant Therapeutics logo

Resonant Therapeutics

resonantrx.com

For-Robin - Quick Facts

Who are For-Robin's competitors?

Companies similar to For-Robin include Robin Care, SunnyBay BioTech, Grid Therapeutics and Nantkwest.

When was For-Robin founded?

For-Robin was founded in 2012.

Where is For-Robin's headquarters located?

For-Robin's headquarters is located in New York City, NY, US.

When was For-Robin's last funding round?

For-Robin's most recent funding round was for $2M (USD) in May 2015.

How much has For-Robin raised to-date?

As of May 4, 2015, For-Robin has raised a total of $2M (USD).

How many employees does For-Robin have?

For-Robin has 2 employees as of Feb 4, 2024.

For-Robin - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Customer
  • Enterprise
Main Product
  • Cancer Treatment
  • Immunotherapy
Tags
  • Consulting
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified